{
    "clinical_study": {
        "@rank": "80491", 
        "acronym": "PRENECAL", 
        "arm_group": [
            {
                "arm_group_label": "Potassium citrate", 
                "arm_group_type": "Experimental", 
                "description": "Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected  gestational age."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day."
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the efficacy and safety of oral potassium citrate on the Prevention of\n      nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo\n      controlled trial."
        }, 
        "brief_title": "Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nephrocalcinosis", 
        "condition_browse": {
            "mesh_term": "Nephrocalcinosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Premature infants of both sexes born at the Hospital Clinic of Barcelona.\n\n          2. Corrected gestational age below 32 weeks and lower birth weight 1500gr.\n\n          3. Survivors at 7 days old.\n\n          4. Clinically stable, in the opinion of the investigator, at the time of inclusion.\n\n          5. That, properly informed, parents and / or legal guardians give written consent to\n             allow the participation of the infant in the study and submit to the tests and\n             examinations that it entails\n\n        Exclusion Criteria:\n\n          1. Renal malformations, cardiac or gastrointestinal prenatal or postnatal diagnosis.\n\n          2. Chronic renal failure (serum creatinine> 1.5 mg / dL or an increase of 0.3 mg / dL /\n             day and / or oliguria defined as diuresis <0.5 mL / kg / hour after the first day of\n             life)\n\n          3. Treatment with furosemide or dexamethasone\n\n          4. Addison's disease.\n\n          5. Persistent severe metabolic alkalosis.\n\n          6. Impossibility of oral feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Weeks", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756547", 
            "org_study_id": "PRENECAL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Potassium citrate", 
                "description": "Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected  gestational age or unacceptable toxicity develops.", 
                "intervention_name": "Potassium Citrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Potassium Citrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nephrocalcinosis", 
            "Extreme premature"
        ], 
        "lastchanged_date": "December 26, 2012", 
        "location": {
            "contact": {
                "email": "jpich@clinic.ub.es", 
                "last_name": "Judit Pich Mart\u00ednez, Pharmacist", 
                "phone": "0034 93 227 54 00", 
                "phone_ext": "2815"
            }, 
            "contact_backup": {
                "email": "fbotet@clinic.ub.es", 
                "last_name": "Francisco Botet Mussons, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Cl\u00ednic de Barcelona"
            }, 
            "investigator": {
                "last_name": "Francisco Botet Mussons, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature.", 
        "overall_contact": {
            "email": "jpich@clinic.ub.es", 
            "last_name": "Judit Pich Mart\u00ednez, Pharmacist", 
            "phone": "0034 93 227 54 00", 
            "phone_ext": "2815"
        }, 
        "overall_contact_backup": {
            "email": "fbotet@clinic.ub.es", 
            "last_name": "Francisco Botet Mussons, MD"
        }, 
        "overall_official": {
            "affiliation": "Hospital Clinic of Barcelona", 
            "last_name": "Francisco Botet Mussons, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "incidence of nephrocalcinosis in extremely preterm infants", 
            "measure": "incidence of nephrocalcinosis in extremely preterm infants", 
            "safety_issue": "Yes", 
            "time_frame": "38-40 weeks of corrected gestational age"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756547"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Clinic of Barcelona", 
            "investigator_full_name": "Juan A. Arnaiz", 
            "investigator_title": "Project manager Clinical Trials Unit", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine whether the administration of potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks", 
                "measure": "Determine whether the administration of potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "38-40 weeks of corrected gestational age"
            }, 
            {
                "description": "To determine whether administration of potassium citrate in extreme premature infants improves the levels of phosphorus, potassium, sodium, citrate, creatinine, oxalate, and ratio citrate / calcium and ph in urine in each treatment arm at the 38-40 weeks.", 
                "measure": "To determine whether administration of potassium citrate improves the levels of  urinary phosphorus, potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value", 
                "safety_issue": "Yes", 
                "time_frame": "38-40 weeks of corrected gestational age"
            }, 
            {
                "description": "Determine whether the administration of potassium citrate in extreme premature neonates improves the plasma levels of sodium, potassium, creatinine, calcium, and blood ph value in each of the branches of treatment at 38-40 weeks.", 
                "measure": "Determine whether the administration of potassium citrate improves the plasma levels of sodium, potassium, creatinine, calcium, and ph value.", 
                "safety_issue": "Yes", 
                "time_frame": "38-40 weeks of corrected gestational age"
            }, 
            {
                "description": "To determine the incidence of adverse events and serious adverse events related to study treatment.", 
                "measure": "To determine the incidence of adverse events and serious adverse events related to study treatment.", 
                "safety_issue": "Yes", 
                "time_frame": "38-40 weeks of corrected gestational age"
            }
        ], 
        "source": "Hospital Clinic of Barcelona", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Juan A. Arnaiz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}